Oncology medications are manufactured and developed by a diverse spectrum of enterprises ranging from massive multinational pharmaceutical corporations to specialized clinical-stage biotechnology firms. Prominent global leaders such as Roche, Merck, Novartis, Pfizer, and AstraZeneca command significant commercial market share with blockbuster therapies, while smaller biotech innovators continuously pioneer advanced cellular immunotherapies, antibody-drug conjugates, and precision-targeted molecules.